EDAP TMS reports preliminary Q4 revenue $21.3M, consensus $18.7M

“Our fourth quarter and full-year 2023 revenues each hit record levels driven by increased demand for Focal One Robotic HIFU and solid execution from our capital sales and regional clinical teams,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “During the fourth quarter, we saw growing demand for Focal One from both leading academic and community hospitals across global markets. Of particular significance was the increasing number of Focal One HIFU procedures in the U.S. which grew by 136% year-over-year. Entering 2024, our pipeline remains strong, and we anticipate sustained business momentum as Focal One Robotic HIFU becomes a necessary treatment option in the management of prostate cancer. As the number of Focal One HIFU procedures continue to grow, we also anticipate greater patient awareness to help drive further demand as men seek out less invasive treatment options with the potential for preserving both sexual function and urinary control. While we are still in the early stages of growth for this market, it is becoming increasingly clear that urologists are adopting the Focal One platform, and we are excited about the opportunities that lie ahead for our technology and our company throughout 2024.”